- La psoriasi genitale è spesso associata ad un significativo impatto sulla health-related quality of life (HRQoL), con una maggiore compromissione della salute sessuale rispetto alle forme di malattia senza coinvolgimento genitale. Tale forma è spesso sottodiagnosticata e sottotrattata.
- I risultati del presente studio mostrano che i pazienti trattati con ixekizumab hanno raggiunto miglioramenti clinicamente significativi dei sintomi della psoriasi genitale, della HRQoL e dell’impatto della malattia sulla vita sessuale, che sono stati mantenuti fino a 1 anno.
Genital psoriasis (GenPs) has been reported in up to 63% of patients with psoriasis. It is often associated with significant impairment of health-related quality of life (HRQoL), including a significantly greater impact on sexual health than psoriasis with no genital involvement. Despite its prevalence and burden, GenPs is often underdiagnosed and undertreated.
Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting interleukin-17A (IL-17A), is the only United States Food and Drug Administration-approved treatment for patients with moderate-to-severe plaque psoriasis that includes labelling information about successful treatment of patients with genital involvement.6 In the IXORA-Q trial, IXE provided significant improvements in HRQoL and in the sexual impact of GenPs following 12 weeks of treatment.7, 8 Here, we report the persistence of these improvements through 52 weeks.
Our results suggest IXE-treated patients achieved significant clinical improvements in GenPs symptoms, HRQoL, and the sexual impact of GenPs that persisted for up to 1 year, supporting the previous results of the IXORA-Q study and IXE as an efficacious treatment option for moderate-to-severe GenPs.